ALIBABA-CLOUD
18.9.2020 05:02:07 CEST | Business Wire | Press release
As the digital technology and intelligence backbone of Alibaba Group, Alibaba Cloud is experiencing continuous growth alongside its customers across different parts of the world. Over the years, it has made relentless efforts to serve clients from every industry, helping them accelerate their business development and navigate the challenges of these volatile times.
Cloud computing and AI technology have been shown to be the cornerstone for businesses seeking to be fully equipped in the digital era, especially following the global outbreak of COVID-19. At the 12th Apsara Conference: Leap into the Future of Digital Intelligence, customers from various sectors, including aviation, leisure and hospitality, education, and e-commerce and retail, share their growth and success stories achieved together with Alibaba Cloud.
“It is our utmost pleasure to see our customers experience a seamless transition into more digitalised operations,” said Selina Yuan, President for International Business, Alibaba Cloud Intelligence. “As a leading global cloud service provider, we take pride in supporting organizations leverage the advantages of our trusted cloud and AI technology, as they fully unlock the potential of their businesses and develop sustainable growth with us. We will continue to enhance our products and services as we leap into the future of digital intelligence.”
Soar higher
In the face of the complex challenges imposed by the spread of the COVID-19 pandemic and the resulting global travel restrictions, Garuda Indonesia (Garuda), the flag carrier of Indonesia that has been providing air transportation for the last 70 years, has chosen Alibaba Cloud as its trusted cloud service provider, as it is determined to implement digital transformation solutions that will enhance its agility and competitiveness in the aviation industry through improved, reliable and highly efficient IT operations.
Thanks to Alibaba Cloud’s robust database and network technology, as well as its IT architecture design service and advice on resource optimization, the airline has been able to significantly improve the performance and service reliability of its core applications, ranging from ticketing, onboarding, and crew management to customer membership management. Since the migration of its business-critical applications to Alibaba Cloud, Garuda has seen great network latency reduction and improved cost efficiency. The airline also takes a shorter time to release and deploy a new application and has enhanced the efficiency of its overall application operations.
Skip the queue
In Malaysia, Resorts World Genting’s upcoming outdoor theme park Genting SkyWorlds will adopt the Advanced Virtual Queue (VQ) Solution powered by Alibaba Cloud to enhance the customer experience. The VQ Solution is a comprehensive system that leverages Artificial Intelligence (AI) and integrates five algorithm modules – Dynamic VQ Slot Prediction, Dynamic Gamification Management, Itinerary Planning, Incentive Recommendation and Crowd Analysis and Prediction. These modules combine to enable more efficient crowd management and to reduce waiting times dynamically.
The solution will allow visitors to plan their entire experience from start to finish before they even reach the theme park. Visitors will be able to download the Genting SkyWorlds’ VQ Mobile App and purchase their tickets online at their convenience. Once the tickets are booked, the VQ Mobile App will allow visitors to plan their itinerary or provide them with an alternative optimised recommended itinerary to offer them a customised experience based on their preferences.
Learn without barriers
Rooted in Singapore, I Can Read (ICR) is an English literacy education service provider for kindergarten and elementary school students across 200 centers and schools in Asia and the Middle East. The organization promotes a uniquely structured curriculum to help children overcome difficulties in reading. One of the biggest challenges faced by the company during the COVID-19 pandemic was the closure of its learning centers in markets where face-to-face classes were prohibited. When trying to move the classes online, ICR encountered several technical barriers – for example, unstable Internet connectivity, the lack of a sound cloud infrastructure, and the need to manually migrate its student database to the designated e-learning platform and re-create more than 7,000 timetables.
To cope with these difficulties, ICR turned to Alibaba Cloud for support. By implementing relevant solutions, such as database storage on cloud and SMS service, the company managed to engage regional customers better with timelier updates on class changes and subsequent arrangements. This has effectively helped the company to stay focused on its business mission of delivering education through both online and offline channels.
Integrate the marketplace, offline and online
WEMART is one of the largest Asian supermarket chains in the Middle East. Its bricks and mortar storefronts have been seriously affected by the COVID-19 pandemic, while its online business volume has increased sharply, pressuring the company to better consolidate its offline and online resources and accelerate its digital transformation.
To power its next phase of growth, WEMART chose to tie up with Alibaba Cloud, which offered a comprehensive online-to-offline shopping solution that combines the strengths of an in-store experience with digital marketing, supporting the operation flow by managing payment gateways, transaction processing and customer membership. In addition, the customer experience was enhanced by other features that came with the solution. For example, the AliMe chatbot, an AI-powered virtual assistant, can handle 60-70% of consumer queries and after-sales service requests on a 24/7 basis, narrowing the communication gap between the retailer and its buyers and greatly improving both operational efficiency and consumer responsiveness.
About Alibaba Cloud
Established in 2009, Alibaba Cloud (alibabacloud.com), the digital technology and intelligence backbone of Alibaba Group, is among the world’s top three IaaS providers, according to Gartner. It is also the largest provider of public cloud services in China, according to IDC. Alibaba Cloud provides a comprehensive suite of cloud computing services to businesses worldwide, including merchants doing business on Alibaba Group marketplaces, start-ups, corporations and public services. Alibaba Cloud is the official Cloud Services Partner of the International Olympic Committee.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200917006047/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom